Considering HIL’s dominant market position in the domestic fiber cement sheet industry and its commitment to achieve USD 1 bn revenue over next 3-4 years, we continue to value the stock at 10xFY26e EPS of Rs. 309.3 to arrive at a target price of Rs. 3093. We continue to have a “Buy” rating on the stock
We thereby downgrade BSE to REDUCE, based on regulatory uncertainty, expected growth moderation in FY26E and rich valuations. Our target price of INR 2,860 is based on 35x (vs 40x earlier) core FY26E PAT + CDSL stake + net cash ex SGWe thereby downgrade BSE to REDUCE, based on regulatory uncertainty, expected growth moderation in FY26E and rich valuations. Our target price of INR 2,860 is based on 35x (vs 40x earlier) core FY26E PAT + CDSL stake + net cash ex SGWe thereby downgrade BSE to REDUCE, based on regulatory uncertainty, expected growth moderation in FY26E and rich valuations. Our target price of INR 2,860 is based on 35x (vs 40x earlier) core FY26E PAT + CDSL stake + net cash ex SG
TBO Tek Limited is a top travel distribution platform operating in 100+ countries. The company’s platform connects suppliers (hotels, airlines, car rentals, cruises, etc.) and buyers (travel agencies, tour operators, etc.) through a two-sided technology platform
The Anup Engineering (TAEL) is one of the leading manufacturers of process equipment like heat exchangers, vessels, reactors, columns etc. Company supplies this equipment to sectors like oil & gas, petrochemicals, chemicals, fertiliser, power, aerospace and other process Industries in India and worldwide
The company is well-placed to cater to the niche segment with strong origination skills, understanding of the customers’ needs as well as focus on smaller cities. We expect these factors will help in garnering market share going ahead.
Company Overview: Indegene Ltd is a technology led digital commercialization provider to the life science industry, including biopharmaceutical, emerging biotech and medical device companies. The company provides technology led expertise and capabilities that assists clients with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaint management and sales & marketing services. Indegene operates across i) Enterprise […]
UltraTech is strongly placed to benefit from its aggressive capacity addition plans with focus on further reducing cost structure. We expect revenue to grow at ~10.8% CAGR over FY24-26E while EBITDA and PAT are expected to grow at 18.1% and 21.2% CAGR respectively over the same period
The dividend yield is computed based on the closing price of 30th April 2024. We have considered companies that have consistently paid dividend in the last 3 years – i.e FY23/CY22, FY22/CY21 and FY21/CY20
The company during the quarter has reported 58.6%/71.2%/35.5% YoY growth in Sales/EBIDTA/PAT to Rs 289.4 cr/Rs 92.9 cr/ Rs 43.0 cr respectively. The full year FY24 Sales/EBITDA/PAT were up 59.0%/61.6%/47.5% YoY to Rs 1,023.9 cr/ Rs 336.8 cr/ Rs 161.7 cr respectively. The EBITDA margin for FY24 remained stable at 32.9% up 51 bps YoY. The overall full year performance in terms of revenue and EBITDA were higher than our expectations, however profit marginally missed our expectation on account of higher interest costs
We have assigned BUY rating on GLS, on the back of proven execution capabilities, strong financials and long-term expansion plans in APIs and CDMO. We believe the change of ownership could be beneficial especially on the expansion front
Recent Comments